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Abstract 
Background: Neoadjuvant chemotherapy with concurrent docetaxel, doxorubicin and cy-
clophosphamide is commonly used for patients with locally advanced breast cancer. Epirubicin 
is another anthracycline used in breast cancer but the concurrent use of epirubicin and taxane 
is not well-established. We conducted a single institution, phase II study to assess the efficacy 
and safety of concurrent docetaxel, epirubicin and cyclophosphamide (TEC) as a neoadjuvant 
chemotherapy regimen in breast cancer. Methods: Patients with newly diagnosed locally 
advanced breast cancer defined as T2 >3 cm, T3, T4 with any N, or any T with N1-3 were 
eligible. A chemotherapy regimen of docetaxel 75mg/m
2, epirubicin 75mg/m
2 and cyclo-
phosphamide 600mg/m
2 was given with filgrastim support every 3 weeks for 6 cycles. The 
primary end-point was pathologic complete response rate. Results: Twenty patients were 
enrolled from 2003 to 2006. The median age was 51 (29-70) year-old. Eight patients were 
premenopausal. Ten patients had positive hormone receptors. Four patients had HER2
 pos-
itive receptor. Nineteen patients completed six cycles of TEC chemotherapy. The pathologic 
complete response rate was 25%. Eight of sixteen patients with N1-3 disease had pathological 
negative lymph nodes. With a median follow up of 57.5 (16-71) months, four patients relapsed 
including one death from recurrence. The estimated 5 year relapse-free survival was 79.3% 
and the 5-year overall survival was 94.7%. No patient had cardiac failure or death during 
treatment. The most common grade 3-4 toxicity was neutropenia (35%). Conclusion: TEC 
regimen is a well- tolerated and effective neoadjuvant chemotherapy regimen for locally ad-
vanced breast cancer that results in a pathologic complete response rate of 25%. 
Key words: Neoadjuvant Chemotherapy, Docetaxel, Epirubicin, Cyclophosphamide, Locally Ad-
vanced, Breast Cancer 
Introduction 
Neoadjuvant chemotherapy is a standard of care 
for  patients  with  locally  advanced  breast  cancer. 
Compared to adjuvant therapy in which there is no 
measurable disease, the primary tumor can be used as 
a  surrogate  marker  of  occult  metastatic  disease  re-
sponse  in  the  setting  of  neoadjuvant  therapy.  The 
hypothesis is that if the primary tumor responds well 
to  systemic  chemotherapy,  the  systemic  micrometa-
static disease should respond as well and will result in 
improved survival. The change in tumor size can be 
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assessed by either a clinical examination or by imag-
ing  studies.  Therefore,  neoadjuvant  chemotherapy 
allows the clinician to perform a real-time assessment 
of tumor response and offers the flexibility of chang-
ing therapy if patients do not show an adequate re-
sponse to the current chemotherapy.1 Several studies 
have demonstrated that the pathological response to 
neoadjuvant therapy is a marker for long-term sur-
vival.2  In  addition,  neoadjuvant  therapy  provides  a 
platform  to  identify  new  molecular  and  genetic 
markers to predict tumor response. 
There is no standard neoadjuvant chemotherapy 
regimen. In the United States, four cycles of doxoru-
bicin and cyclophosphamide (AC) followed by four 
cycles of taxane (paclitaxel or docetaxel) is commonly 
used. In Canada and Europe, fluorouracil, epirubicin 
and cyclophosphamide for 6 cycles is more popular. 
The addition of taxane augments the efficacy of an-
thracycline-based  chemotherapy  regimen.  The 
NSABP-B27  study  demonstrated  that  preoperative 
administration  of  docetaxel  following  AC  increased 
the pathological complete response (pCR) rate from 
13.7%  to  26.1%.2  An  M.D.  Anderson  study  showed 
adding  paclitaxel  prior  to  preoperative  fluorouracil, 
doxorubicin  and  cyclophosphamide  regimen  in-
creased a pCR rate from 15.7% to 28.2%.3 Compared 
to sequential treatment, concurrent use of taxane with 
anthracycline  may  provide  a  similar  response  but 
with shorten treatment duration. The GeparTrio trial 
found that the six cycles of docetaxel, doxorubicin and 
cyclophosphamide (TAC) produced a pCR of 21% if 
the primary tumor size decreased by ≥ 50% and a pCR 
of 5.3% if the decrease was < 50% after two cycles of 
chemotherapy.1,4 Epirubicin has comparable efficacy 
to doxorubicin but less cardiotoxicity. Theoretically, 
the concurrent administration of docetaxel, epirubicin 
and cyclophosphamide (TEC) should be as effective 
as TAC regimen but may have a less toxicity profile. 
The use of TEC regimen as neoadjuvant chemother-
apy has not been  well-established. We conducted a 
single institution phase II study to assess the efficacy 
and  safety  of  neoadjuvant  TEC  regimen  in  patients 
with locally advanced breast cancer.  
Patients and Methods 
Patient  population:  All  patients  signed  an  in-
formed consent form. The inclusion criteria were fe-
male  patients  with  histologically  confirmed  breast 
cancer; either T2 > 3 cm, T3, T4 with any N, or any T 
with N1-3, and M0. Patients were registered within 45 
days of diagnosis. The age was ≥ 18 years old. Patients 
were required to have Eastern Cooperative Oncology 
Group performance status scale 0-1 and were candi-
date for systemic chemotherapy. The exclusion crite-
ria were patients who were pregnant or lactating, had 
undergone lumpectomy, had received any prior sys-
temic or radiation therapy for the breast cancer, had 
any other serious medical or psychiatric illness, had 
any history of chronic liver disease, active infection, 
prior malignancies except non-melanoma skin cancer, 
in-situ  carcinoma  of  the  cervix,  or  other  non-breast 
cancer if disease free > 5 years. 
Biopsy:  Patients  with  palpable  axillary  lymph 
nodes underwent an excisional or core needle biopsy 
of  the  nodes.  If  there  was  no  palpable  disease,  the 
patient  underwent  standard  pre-surgical  ra-
dio-lymphatic  mapping followed by sentinel lymph 
node biopsy. 
Initial  evaluation:  All  patients  had  whole  body 
bone scan, computed tomography scan of chest, ab-
domen and pelvis to rule out distant metastasis. Pa-
tients  had  ultrasound,  mammography,  or  magnetic 
resonance imaging to determine the longest diameter 
of the primary breast tumor. Patients had a left ven-
tricular  ejection  fraction  measurement  by  either 
MUGA  scan  or  Echocardiogram.  For  patients  who 
were  of  childbearing  potential,  negative  pregnancy 
test was documented. 
Neoadjuvant  chemotherapy:  All  eligible  patients 
received 6 cycles of neoadjuvant chemotherapy con-
sisting of docetaxel 75 mg/m2, epirubicin 75 mg/m2 
and cyclophosphamide 600 mg/m2 every 3 weeks. All 
three agents were given on day 1 of each cycle. Pa-
tients were offered either filgrastim 5 µg/kg subcu-
taneously on day 5-15 or pegfilgrastim 6 µg subcuta-
neously on day 2. To receive chemotherapy, patients 
must  have  absolute  granulocyte  count  >  1,500/µl, 
platelet  count  >  100,000/µl,  hemoglobin  >  10  g/dl, 
creatinine < 1.5 x upper limit normal (ULN), AST < 1.5 
x UNL, alkaline phosphates < 5 x UNL, and total bil-
irubin < ULN. Administration of chemotherapy might 
be delayed because of hematological, renal or gastro-
intestinal toxicity on day 1 of any cycle. No dose re-
duction was allowed for hematological toxicities only.  
Tumor  size  was  assessed  after  two  cycles  of 
chemotherapy.  If  the  tumor  remained  stable  or 
shrank, the patient would proceed with another four 
cycles of chemotherapy treatment. If the patient had 
progressive disease, she would then be removed from 
the study and further treatment would be given ac-
cording to the best standard of care. 
Surgery, radiation and other therapy: Three to six 
weeks after completion of last cycle of neoadjuvant 
chemotherapy, the patients underwent primary sur-
gical  resection.  Surgery  for  the  primary  tumor  was 
either lumpectomy or mastectomy and the choice was 
left to the surgeon according to best practice stand-
ards or available protocols. Axillary lymph node dis- Journal of Cancer 2012, 3 
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section was performed on all patients with nodal in-
volvements.  All  lumpectomy  patients  had  adjuvant 
radiation  therapy.  The  radiation  oncologist  deter-
mined the need for chest wall radiation for mastec-
tomy patients and /or axillary radiation according to 
best  practice  standards.  Adjuvant  anti-hormone 
therapy was given to patients with positive hormone 
receptors.  Adjuvant  trastuzumab  was  given  if  the 
tumor  was  HER2  receptor  positive.  After  surgery, 
patients were followed every 3 months for 2 years and 
then every 6 months for another 3 years. Further dis-
ease follow up was at the discretion of the treating 
physician. 
Toxicity: All patients who received neoadjuvant 
chemotherapy  were  evaluated  for  treatment  related 
toxicity. Adverse events were summarized using the 
Common  Toxicity  Criteria  of  the  National  Cancer 
Institute for Adverse Events, version 3.0. 
Statistical analysis: The primary endpoint of the 
study was pCR rate. The pCR was defined as no his-
tological evidence of invasive tumor cells in the sur-
gical breast specimen and axillary lymph nodes. The 
secondary  endpoints  were  clinical  response  to  neo-
adjuvant chemotherapy, adverse events, relapse-free 
survival (RFS) and overall survival (OS). The primary 
tumors were evaluated by imaging and physical ex-
amination at baseline, after the second cycle and the 
last cycle of chemotherapy. RECIST guidelines were 
used to document clinical response. RFS was defined 
as the time from the date of histological diagnosis to 
the first date of disease relapse or the date of death of 
any cause. OS was defined as the time from the date of 
diagnosis to the date of death of any cause. 
A 25% of pCR rate and a 70% of clinical response 
rate was anticipated. Approximately 40 patients were 
planned to be enrolled into this protocol to produce a 
confidence interval of 53.5% to 83.4%. The study was 
terminated  early  after  an  interim  analysis  was  con-
ducted half way through the proposal. The RFS and 
OS were estimated using the Kaplan-Meier analysis. 
Results  
Patient characteristics: Twenty one female patients 
were registered from Dec 2003 to Dec 2006. One pa-
tient was excluded because of a history of papillary 
thyroid cancer. Twenty patients were evaluated (Ta-
ble 1). The median age was 51 year-old (range 29-70). 
Eight  of them (40%) were premenopausal. Two pa-
tients had invasive lobular carcinoma and the others 
had invasive ductal carcinoma. One patient had in-
flammatory  breast  cancer.  The  median  size  of  the 
primary tumor was 5.5 (range 0-11) cm by physical 
examination  and  3.3  (range  1.5-12)  cm  by  imaging 
studies.  Sixteen  patients  (80%)  had  axillary  lymph 
node involvements. Ten patients (50%) had positive 
hormone receptors. Four patients (20%) were HER2 
receptor positive. All but one patient received adju-
vant  radiation  therapy.  All  patients  with  positive 
hormone receptor received adjuvant hormonal treat-
ment at a median duration of 52 (range 12-60) months. 
The  4  patients  with  HER2  positive  tumor  also  re-
ceived 12 months adjuvant trastuzumab treatment. 
 
 
Table 1. Baseline clinical characteristics of the study pop-
ulation (N=20) 
Characteristic  No. 
Age, years   
Mean  51 
range  29-70 
Menopausal status   
premenopausal  8 
postmenopausal  12 
Clinical stage   
T2  12 
T3  7 
T4  1 
Clinical nodal status   
N0  4 
N1  13 
N2  3 
Scarf-Bloom-Richardson tumor grade   
I  3 
II  9 
III  8 
Tumor hormone receptor status   
Positive  10 
negative  10 
Tumor HER2 receptor status   
positive  4 
negative  16 
 
 
 
Outcome:  Fourteen  patients  (70%)  had  lumpec-
tomy and six patients (30%) underwent mastectomy. 
For three of these six patients, mastectomy was done 
because of presence of residual disease. Two mastec-
tomies were performed because patients had multi-
centric disease. One patient was offered lumpectomy 
but she decided to have mastectomy.  
Nineteen patients (95%) showed primary tumor 
shrinkage measured by either clinical examination or 
imaging studies after six cycles of TEC chemotherapy. 
Five  patients  had  pCR  (25%).  Sixteen  patients  with 
nodal involvement had lymph node dissection after  Journal of Cancer 2012, 3 
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completion of chemotherapy; eight of them (50%) had 
pathological negative lymph nodes.  
With  a  median  57.5  (range  16-71)  months  fol-
low-up, four patients (20%) relapsed. All of them had 
lymph nodes involvement at diagnosis and failed to 
achieve pCR. Two of them had triple negative disease, 
one patient was ER-PR-HER2+ and another one was 
ER+PR+HER2-  .  The  median  time  of  relapse  was  43 
months (range 22-50). One patient had a relapse at 22 
months and died at 24 months after diagnosis. One 
relapsed patient transferred her care to another insti-
tution.  One  patient  who  was  in  remission  at  22 
months moved out and lost follow up. All other pa-
tients remained alive at the latest follow up. The es-
timated  5-year  RFS  was  79.3%  (Figure  1)  and  the 
5-year OS was 94.7% (Figure 2). 
 
 
Figure 1. Relapse-Free Survival 
 
 
Figure 2. Overall survival 
Safety and Tolerability: No patients had progres-
sive  disease  after  two  cycles  of  chemotherapy.  All 
patients proceeded to receive a full course of treat-
ment and were assessable for toxicity. Patients toler-
ated the chemotherapy well. Nineteen patients (95%) 
completed all six cycles of TEC chemotherapy. One 
patient  had  five  cycles  of  chemotherapy.  The  early 
discontinuation was due to emotional stress but not 
due  to  adverse  effects.  One  hundred  twenty  five 
(99.2%) of 126 planned cycles of TEC were adminis-
tered. No dose reduction of epirubicin or cyclophos-
phamide was required. For three patients (15%), the 
dose of docetaxel was reduced by 25% after cycle 3, 4, 
and  5  respectively  because  of  grade  3  peripheral 
neuropathy.  Any  adverse  event,  irrespective  of 
whether it is directly caused by chemotherapy, was 
taken into account (Table 2). Two patients had grade 
1-2 tachycardia and 1 patient had palpitation. No pa-
tient  developed  cardiac  failure.  The  most  common 
grade  3-4  adverse  effects  were  neutropenia,  35%. 
Three patients (15%) had neutropenic fever. No death 
occurred during the treatment.  
Discussion 
This phase II study demonstrates that TEC reg-
imen  is  an  efficacious  neoadjuvant  chemotherapy 
regimen with a 25% pCR rate for patients with locally 
advanced breast cancer. A German study using TEC 
neoadjuvant chemotherapy regimen recently reported 
the same pCR rate.5 This supports that our results are 
likely to be reproducible. 
The 25% pCR rate in our study is higher than 
that of most of the old chemotherapy regimens and is 
comparable to that of 26% in NSABP-B27 study6 and 
that  of  21%  in  GeparTrio  trial4  (Table  3).  In 
NSABP-B27  study,  chemotherapy  of  AC  x  4  cycles 
was followed by docetaxel x 4 cycles.6 In GeparTiro 
trial, patients were given  six cycles of TAC chemo-
therapy. A 21% pCR rate was obtained from a selected 
population in which patients demonstrated ≥ 50% of 
shrinkage of tumor after two cycles of TAC chemo-
therapy.4 For those who had < 50% of response after 
two cycles of TAC treatment and continued to receive 
six  cycles  of  TAC  chemotherapy,  the  pCR  rate  was 
only  5.3%.1  The  definition  of  pCR  was  different 
among these three studies (Table 3). In NSABP-B27 
study, pCR was defined as no invasive tumor only in 
the primary breast site but residual tumor in regional 
lymph  node  was  allowed.6  In  GeparTrio  trial,  pCR 
was  defined  as  no  microscopic  evidence  of  viable 
tumor  (invasive  and  non  invasive)  in  all  resected 
specimens  including  breast  and  regional  lymph 
nodes.4 In our study, pCR was defined as absence of 
invasive tumor in both breast and lymph nodes but in  Journal of Cancer 2012, 3 
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situ cancer can be present. If only NSABP-B27 criteria 
is  used  for  a  direct  comparison,  the  pCR  rate  of 
NSABP-B27, GeparTrio and our study would be 26%, 
30.6% and 30% respectively. In our study, one patient 
who achieved pCR was not included in the analysis 
because she had a history of thyroid cancer. Taking 
account of this patient, the pCR rate would be even 
higher in our study. 
Table 2. Selected Adverse Events on 119 Cycles of 
Chemotherapy (%, any grade 3/4 or >3 events for grade 
1/2) 
Events  Grade 1/2  Grade 3  Grade 4 
nausea/vomiting  70     
constipation   55     
diarrhea  40  10   
mucositis  35     
anorexia  30     
abdominal pain  30     
dyspepsia  30     
fatigue  85     
mylgia  25  5   
Bone pain  30     
Chest pain  5  5   
Hot flash  45  5   
Port insertion site reac-
tion 
15  5   
alopecia  60     
Cutaneous reaction  40     
syncope    15   
dizziness  20     
headache  20  5   
Peripheral neuropathy  15  15   
Eye irritation  35     
Taste change  20     
Runny nose  35     
insomnia  35     
Mood change  15  10   
Yeast infection  30     
Sinusitis/URI  35     
UTI  20     
gastroenteritis    10   
dehydration    10   
hyperglycemia  10  5   
edema  20     
neutropenia  10  10  25 
lymphopenia  5  10  5 
Febrile neutropenia    15   
anemia  70     
 
The patient characteristics were different among 
NSABP-B27,  GeparTrio  and  our  study.  There  were 
more  patients  with  advanced  disease  in  our  study. 
When there was no nodal involvement, only patients 
with primary tumor ≥ 3 cm in diameter were eligible. 
More than 80% of patients had biopsy proved nodal 
disease.  The  NSABP-27  trial  included  14%  patients 
with tumors ≤ 2 cm and 70% of node negative dis-
ease.6 The GeparTrio trial included patients with T1 
disease  and  47%  of  the  patients  had  no  nodal  in-
volvement  (N0)4.  This  study  had  a  slightly  lower 
percentage of hormone receptor positive patients and 
less  HER2+  patients  (Table  3).  In  NSABP-27  and 
GeparTrio  trial,  no  patients  received  trastuzumab 
therapy. At the time when this trial was designed and 
implemented, neoadjuvant trastuzumab therapy was 
not standard of care. All HER2+ patients then received 
one-year  adjuvant  trastuzumab  treatment.  The  an-
ti-HER2  therapy  was  given  postoperatively,  it  thus 
might improve RFS and OS but should not affect pCR 
rate. The lower proportion of HER2+ patients in this 
study  should  not  contribute  to  a  higher  pCR  rate. 
Conversely,  patients  with  HER2+  tumors  are  often 
accompanied with topoisomerase-II amplification and 
are more sensitive to docetaxel-based 7 and anthracy-
cline-based  therapy.8,9  Two  studies  have  found  that 
the  overexpression  of  HER2  is  associated  with  a 
higher pCR rate.10,11 Taken together, even our study 
had more patients with advanced disease, a compa-
rable pCR rate was obtained. This supports that TEC 
regimen is a very effective neoadjuvant chemotherapy 
regimen. 
The total planned dose of chemotherapy in this 
study  is  slightly  higher  than  of  NSABP-B27  and 
GeparTrio (Table 4). Nevertheless, a high completion 
rate was achieved. Only one patient did not complete 
the full course of treatment. In NSABP-B27 trial, 5.5% 
of patients did not start docetaxel and in total, 21.2% 
of patients did not complete the full four course of AC 
and four course of docetaxel. In our study, 99.2% of 
chemotherapy  was  actually  administered  compared 
to that of 92.2% in GeparTrio trial. It is worthwhile to 
note  that  there  were  more  elderly  patients  in  our 
study. The percentage of patients who are 60 years of 
age  was  30%  in  our  study,  compared  to  9.5%  in 
GeparTrio4  and  13.9%  in  NSABP-B27.6  The  main 
grade 3-4 toxicity of TEC regimen was neutropenia. 
Its incidence was slightly lower than that in GeparTrio 
trial, 35% vs. 42.1%4 but higher than that of 8.6% in 
NSABP-B27 study.4,6 The incidence of febrile neutro-
penia in our study was, however higher than Gepar-
Trio trial, 15% vs. 7.4%.4 In NSABP-B27 study, 7.3% of 
patients had febrile neutropenia while receiving AC 
but  21.2%  patients  developed  febrile  neutropenia  Journal of Cancer 2012, 3 
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while receiving docetaxel.6 (Table 4) There were more 
grade  3  peripheral  neuropathy  in  our  study  than 
GeparTrio and NSABP-B27 study, 15% vs. 1.3%4 vs. 
2.3%.4,6  Therefore  the  TEC  regimen  should  be  used 
cautiously  for  patients  with  preexisting  peripheral 
neuropathy  or  patients  with  high  risk  to  develop 
neuropathy, such as those with long-term diabetes. 
In  summary,  our  single-institution  phase  II 
study  demonstrated  that  TEC  regimen  is  an  effica-
cious  and  well-tolerated  neoadjuvant  regimen  for 
patients with locally advanced breast cancer. Future 
research  interest  in  neoadjuvant  chemotherapy  in 
locally advanced breast cancer should be the focus of 
using  genetic  profiling  such  as  Oncotype  Dx  in  se-
lecting patients to receive neoadjuvant chemotherapy 
treatment.  
 
 
Table 3. Comparison of patient characteristics, design and pCR rate among NSABP-B27, GeparTrio and our study TEC  
Trial  Node positive   Hormone re-
ceptor negative 
HER2 receptor positive  Planed chemotherapy  Reported 
pCR 
Corrected 
pCR* 
NSABP-B27  30.3%  38.4%**  unknown  All patients were given 8 cycles  26%  26% 
Gepar Trio  53%  40.1%  38.1%  Only those with tumor size 
>50% reduction had 6 cycles 
21%  30.6% 
TEC  80%  50%  20%  All patients were given 6 cycles  25%  30% 
pCR: pathological complete response  
* NSABP-B27 pCR criteria: no invasive disease in the primary tumor was used in all three studies for a comparison.  
** 61.8% of patients have unknown hormone receptor status. For the patients with hormone receptor examined, 38.4% have negative hor-
mone receptors. 
 
 
Table 4. Comparison of total planned chemotherapy dosage, completion rate, neutropenia among NSABP-B27, GeparTrio 
and our study TEC 
  Total chemotherapy dosage (mg)  Completion rate  Grade 3-4 neutro-
penia 
Febrile neutro-
penia 
Trial  Docetaxel  Anthracycline  Cyclophosphamide       
NSABP-B27  400  Doxorubicin 240  2,400  unknown  8.6%  AC 7.3% 
T 21.2% 
Gepar Trio  450  Doxorubicin 300  3,000  92.2%  42.1%  7.4% 
TEC  450  Epirubicin 450  3,600  99.2%  35%  15% 
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